FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

FGEN has been the topic of a number of other reports. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Tuesday, April 1st. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Trading Down 4.9 %

FGEN opened at $0.28 on Monday. The company has a fifty day moving average price of $0.44 and a two-hundred day moving average price of $0.42. FibroGen has a 1-year low of $0.18 and a 1-year high of $1.74. The company has a market cap of $28.26 million, a P/E ratio of -0.23 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million. On average, research analysts forecast that FibroGen will post -0.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Thane Wettig acquired 145,000 shares of FibroGen stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $0.35 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer now owns 543,329 shares of the company’s stock, valued at approximately $190,165.15. This trade represents a 36.40 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Schoeneck acquired 250,000 shares of FibroGen stock in a transaction on Thursday, March 20th. The stock was acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the purchase, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On FibroGen

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares during the period. Geode Capital Management LLC raised its holdings in shares of FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the period. JPMorgan Chase & Co. lifted its stake in FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 1,358,194 shares during the last quarter. Franklin Street Advisors Inc. NC grew its holdings in FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares during the period. Finally, Renaissance Technologies LLC increased its position in FibroGen by 80.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.